USANA Health Sciences (NYSE:USNA) Sets New 1-Year Low – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $26.74 and last traded at $26.87, with a volume of 26579 shares changing hands. The stock had previously closed at $27.24.

Analysts Set New Price Targets

USNA has been the topic of a number of recent analyst reports. DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Trading Up 3.7 %

The firm has a market capitalization of $514.82 million, a P/E ratio of 9.62, a P/E/G ratio of 0.93 and a beta of 0.98. The business’s fifty day moving average is $31.39 and its 200 day moving average is $35.20.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. As a group, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at USANA Health Sciences

In related news, insider David Mulham Mulham sold 3,234 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the transaction, the insider now directly owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joshua Foukas sold 5,732 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,920 shares of company stock valued at $500,285. 0.33% of the stock is currently owned by corporate insiders.

Institutional Trading of USANA Health Sciences

Hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new position in USANA Health Sciences in the 4th quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC acquired a new position in shares of USANA Health Sciences in the third quarter worth $30,000. KLP Kapitalforvaltning AS purchased a new stake in shares of USANA Health Sciences during the fourth quarter worth $83,000. Quantbot Technologies LP acquired a new stake in USANA Health Sciences during the fourth quarter valued at $132,000. Finally, Meeder Asset Management Inc. acquired a new stake in USANA Health Sciences during the fourth quarter valued at $143,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.